IBRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ImmunityBio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$8.42−0.76 (-8.28%)
Close on Oct 19, 2026
- Market cap
- $8.84B
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
ImmunityBio has not reported a dividend
No dividend per share appears in ImmunityBio's annual filings since fiscal 2012.